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In a concerted effort to identify biomarkers for lung and colon carcinomas by genome-wide transcriptional profiling, we describe the
identification and cloning of one such gene as well as two additional closely related genes. Due to the strong sequence homology to the C.
elegans UNC-112 we call this gene URP1, for UNC-112 related protein. We have also isolated the full-length clones for another novel related
gene, URP2 and the previously discovered MIG-2 gene. Collectively, these proteins, together with two from Drosophila, appear to form a
novel membrane-associated FERM and PH domain-containing protein family. Transcriptional analysis shows that only URP1 is significantly
differentially regulated, being over-expressed in 70% of the colon carcinomas and 60% of the lung carcinomas tested. Quantification of
URP1 expression by qRT-PCR showed up-regulation of the gene by 60-fold in lung tumors and up to nearly 6-fold in colon tumors. Northern
blot analysis of URP1 indicates that normal expression is restricted to neuromuscular tissues. In contrast, the expression of URP2 appears to
be confined primarily to tissues of the immune system. SNP analysis of URP1 reveals that it is highly polymorphic, containing seven sites,
four of which are in the coding region and one position that results in the interchangeable substitution of glutamic acid and lysine. Finally, we
have shown that the genomic structure for all three genes is nearly identical with all encoded by 15 exons although URP1 gene localized to
chromosome 20p13, URP2 to 11q12 and MIG-2 to 14q22. This conserved exon structure suggests that all three members probably arose by
gene duplication from one ancestral gene. The presence of multiple FERM domains characteristic of cytoplasmic plasma membrane to
cytoskeleton linkers and a PH domain typical of membrane-anchored proteins involved in signal transduction suggest an important role for
URP1 in tumorigenesis.D 2003 Elsevier Science B.V. All rights reserved.Keywords: Cancer; UNC-112; cDNA microarray; DNA chip; Transcript expression analysis; Cytoskeletal protein; PH domain; FERM domain; URP1; URP2;
MIG-2
1. Introduction therapy or chemotherapy in patients with metastatic disease.Neoplastic diseases of the lung and large intestine are the
two top causes of morbidity and mortality in the United
States, with lung cancer accounting for a staggering 440,000
deaths [1] and colorectal carcinoma for approximately
60,000 deaths annually [2]. In general, lung and colorectal
cancer are only moderately sensitive to traditional radiation0925-4439/03/$ - see front matter D 2003 Elsevier Science B.V. All rights reserv
doi:10.1016/S0925-4439(03)00035-8
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E-mail address: richard.a.mazzarella@pharmacia.com (R. Mazzarella).Therefore, investigation is actively pursued into identifica-
tion of potential molecular targets for therapeutic interven-
tion.
New molecular tools, such as cDNA arrays, allow for a
quantitative measurement of mRNA expression levels of
multiple genes. Studies of modifications that take place in
colon tumors at the level of transcription may lead to
identification of new therapeutic targets. We analyzed gene
expression patterns in dissected normal and malignant
human colon tissue from 10 individuals from each state.
One of the genes found to be up-regulated in carcinoma
samples shows significant homology to the previouslyed.
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which we have named URP1, is also closely related to the
previously identified human mitogen-inducible gene, MIG-
2. In addition, we have also identified another novel MIG-2-
related gene, URP2, which like MIG-2, is not significantly
differentially regulated in most carcinomas.
MIG-2 was found to be serum-inducible in the human
diploid fibroblast cell line WI-38 [4]. Other than the
observation that normal expression of this gene is induced
during the G0! S progression, there is no information
concerning a potential function of MIG-2. The C. elegans
ortholog of MIG-2, UNC-112, has been more extensively
characterized [3]. It is a membrane associated, intracellular
protein that co-localizes with h-integrin in adhesion com-
plexes. Through generation of UNC-112 mutant embryos, it
was further shown that UNC-112 is required for organiza-
tion of h-integrin after its integration into the basal cell
membrane.
UNC-112 may exert its function through binding to the
cytoplasmic tails of integrins and promote cross-linking of
the actin cytoskeleton and formation of dense bodies [5].
This hypothesis is based on the presence of protein 4.1-
ezrin-radixin-moesin (FERM) and pleckstrin homology
(PH) domains. URP1, URP2, MIG-2, UNC-112 and two
genes from Drosophila (CG7729 and CG14991) share a
unique domain structure consisting of two FERM domains
flanking a PH domain. The approximately 30 kDa FERM
domain is found in a family of proteins that mediate linkage
of the cytoskeleton to transmembrane proteins [6]. This
family includes erythroid protein 4.1, ezrin, radixin, moesin
and the Drosophila coracle. FERM domain-containing pro-
teins are believed to bind either directly or indirectly to the
plasma membrane through the FERM domain and can
anchor actin microfilaments. They are thereby thought to
be involved both in the morphogenesis of membrane struc-
tures and in cell adhesion (reviewed in Refs. [7,8]). Most
PH domains investigated to date also serve as membrane-
anchoring domains and bind to some extent to phosphoino-
sitides or inositol phosphates (reviewed in Refs. [9–11]).
They are 100–120 stretches of amino acids that are thought
to be involved in protein–protein interactions with cellular
signaling proteins, similar to Src homology domains 2 and
3. No physiologically significant protein target of PH
domains has yet been identified.2. Materials and methods
2.1. Tissue specimens
Primary tumors were excised from 10 different individ-
uals for each tumor type (breast, colon, lung and kidney)
suffering from various stages of cancer ranging from early
to late stage. Normal colon tissue was excised from 10
sudden death (primarily accident and stroke) individuals.
After RNA isolation, these 10 normal samples were pooledto constitute a normal standard for comparison to each
tumor sample. All patient tissue specimen collection con-
formed to the NIH Guidelines for the Conduct of Research
Involving Human Subjects and the NIH Guidelines For
Writing Informed Consent Documents.
2.2. RNA isolation
RNA was isolated from 10 g tissue using the ToTALLY
RNAk Total RNA Isolation Kit (Ambion). This method is
based on the guanidine thiocyanate, acid phenol:chloroform
procedure of Chomczynski and Sacchi [12]. Poly A+ RNA
was prepared using the OligotexR mRNA kit (Qiagen) as
described by Lashkari et al. [13].
2.3. Microarray analysis
Fluorescently labeled (Cy3, Cy5) cDNA probes were
generated from the RNA samples (Incyte Genomics). Incyte
GA or HG microarray chips were analyzed by competitive
hybridization [14] to each of 10 individuals and were
compared to a normal tissue pool. Once the data were
error-corrected and normalized, the fold increase or decrease
of tumor tissue expression/normal tissue was calculated.
2.4. Real-time quantitative reverse transcription polymerase
chain reaction
The RT-PCR reaction is run with RNA samples on an ABI
PRISM 7700 Sequence Detection System at 25 Al final
volume with 2 Al of the RNA, primers at 100 nM and en-
zymes from SYBR-Green Mix (ABI) as per manufacturer’s
protocol. The thermal cycling conditions are: 40 min at 48
jC, 10 min at 95 jC, followed by 40 cycles of 15 s at 95 jC
and 1 min at 60 jC. Fluorescent signal for the reaction is
collected and characterized as cycle thresholds (Ct). The
primers for URP1 are: 5V-CAGGCACAGTCCTCTCTG-
TTCATAG-3V (forward primer) and 5V-TTAGATAAAA-
GGCCAGGAGTCGTACC-3V(reverse primer). Human
cyclophilin control primers are: 5V-CCCACCGTGTTCT-
TCGACAT-3V(forward) and 5V-TTTCTGCTGTCTTTGG-
GACCTT-3V(reverse).
2.5. Northern blot analysis
Multiple human RNA samples were analyzed using a
Multiple Tissue Northern Blot (Clontech Laboratories) and
either a probe for URP1 corresponding to base pairs 1342–
2031 or a probe for URP2 consisting of the full-length
clone. The probe is labeled with [a-32P]dCTP (New Eng-
land Nuclear) using Prime-It random primer labeling kit
(Stratagene) and purified over NucTrap probe purification
columns (Stratagene). Hybridization is performed for 2 h at
68 jC. Filter is washed at room temperature in 2 SSC/
0.05% SDS for 30 min and at 68 jC in 0.1 SSC/0.1%
SDS for 1 h before exposing to film.
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The genome structures for URP1 and MIG-2 were
determined from Celera Human Genome Assembly Release
25. This release is comprised of both Celera and public
sequence data and represents an estimated 98% total
genome coverage and approximately 4.7 genomic
sequence depth. The underlying genomic sequence data
can be accessed at http://www.celera.com [15].
2.7. Molecular cloning, PCR, and sequencing
Primers were designed to amplify the coding regions of
the URP1 and MIG-2 genes based on sequence found in
the Celera database as follows: forward primer F353
(GCCACAATGCTGTCATCCACTG) with R2426
(CCTTGTTGGTGTGAGCCGAGCACG), and forward pri-
mer F300 (GCGACTGCGAGGCTGGACGCTACGG)
with reverse primer R2392 (TCAATCCTGACCGCCGGT-
CAATTTGTGG) for amplification of URP1 and forward
primer F109 (GGCAGGAAGGAGCCATGGCTCTG-
GACG) was used with reverse primer R2179 (AACAG-
TATTTCTATTCACACC) for amplification of MIG-2. A
mixture of human colon tumor cDNA random primed and
human colon tumor cDNA oligo dT primed was used as a
template for the PCR reactions. PCR reactions contained
133 ng of cDNA template, 0.5 Al of each forward and
reverse primers at 10 AM stock, 0.5 Al of 10 mM dNTP, 2.5
Al of 10 PCR buffer and 1.25 units of Taq DNA
polymerase (Roche, catalog #1418432) and brought up to
25 Al with water. For amplification of URP1, the reaction
was brought to 94 jC for 2 min and subsequently under-
went 30 cycles of denaturation at 94 jC for 30 s, annealing
at 60 jC for 30 s and extension at 72 jC for 1 min. This
was followed by a 5 min extension at 72 jC. Conditions for
PCR of MIG-2 were similar, with the exception of denatu-
ration at 95 jC and annealing at 50 jC. PCR products were
run on a 1% low melting temperature agarose gel (catalog
#50111, FMC Bio Products) containing ethidium bromide
in 1 TAE. Gel bands containing the desired DNA frag-
ment were purified and eluted into 50 Al of water using
Wizard PCR Preps DNA Purification System (Promega
catalog #A7170, Madison, WI). The purified DNA was
used to set up a ligation into the pCR2.1 vector and
transformed into TOP10 cells according to manufacturer’s
instructions (Invitrogen catalog #44-0301, Carlsbad, CA).
One hundred microliters of transformation was plated on
LB with ampicillin and X-Gal plate, and incubated at 37
jC overnight. Colonies were picked the next day and
grown in 1 ml Terrific broth with ampicillin overnight at
37 jC, 250 rpm. Plasmid DNAs were purified using
QiaPrep 96 Turbo Mini prep kit (Qiagen, catalog #27191,
Valencia, CA).
Analysis of an internal database containing sequences
from >200,000 Pharmacia cDNA clones from various
tissues using the predicted URP2 gene sequence revealed
E.J. Weinstein et al. / Biochimica etwo clones encoding the full-length protein in the pSPORT-
1 vector. Each clone was completely sequenced in both
directions using primers corresponding to the predicted
sequence according to conditions described above for
URP1 and MIG-2. Analysis of the two sequences showed
that they differed by a 12 bp insertion. A clone identified
from a brain cDNA library lacked the insertion sequence,
whereas a clone identified in a leukocyte cDNA library
contained it.3. Results
In order to determine which genes are over-expressed in
four prevalent tumor tissues (colon, breast, lung and kid-
ney), microarray analysis of 40,000–60,000 cDNAs repre-
senting about 30,000 genes was performed. In these studies,
the expression in tumor samples from ten individuals for
each tumor type was compared against matched adjacent
non-involved tissue and a normal tissue pool of RNA from
six individuals. The fold increase or decrease for each
cDNA was then calculated by comparing the expression in
each tumor tissue versus normal tissue pool (Table 1).
Interestingly, a novel gene, URP1, and its homologs,
MIG-2 and URP2 show contrasting patterns of expression.
Both the URP1 and MIG-2 genes are represented by two
clones on all tumor arrays, whereas URP2 is only repre-
sented by a single clone on the colon microarray. These
clones were analyzed for over-expression in the colon
tumors. Changes in the expression levels of greater than
2-fold are considered significant. Seven of the ten patients
with colorectal carcinoma (patients 1–4 and 6–8, Table 1)
had reproducible and significant increases of URP1 expres-
sion, whereas no patients showed a significant increase of
MIG-2 or URP2. In contrast, one patient (patient 7, Table 1)
showed a significant decrease in the expression levels of
MIG-2. One potential source of false positive signals in
microarray experiments arises from cross-hybridization
between genes with closely related sequences.
The levels of expression of the URP1 and MIG-2 homo-
logs were also observed in microarray analysis of breast,
kidney and lung tissues utilizing different clones to measure
the changes. No significant changes in either gene were
observed in any renal cell carcinoma samples. While URP1
expression was relatively unchanged in breast tumors, MIG-
2 was significantly increased in two patients (patient 9 and
10, Table 1). In contrast to the data from renal and breast
carcinomas, URP1 was significantly over-expressed in six of
ten lung tumors (patients 2, 3, 6–9, Table 1) while MIG-2
showed over-expression in one sample (patient 4, Table 1).
In our experience, the extent to which genes, that are
over-expressed more than 2-fold in microarray experiments,
are frequently underestimated due to the inability to accu-
rately subtract background hybridization. We have found
that RT-PCR, when normalized with GUS expression,
yields a more accurate determination of increases in mRNA
Table 1
URP1, MIG-2 and URP2 fold change of expression in various tumors by microarray analysis
Tumora Gene Cloneb Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Patient 9 Patient 10 Average
Colon URP1 1658232 2.81 3.52 4.47 4.53 2.10 4.50 2.29 2.58  1.09 1.40 2.71
2242925 2.53 3.05 3.96 4.76 1.95 3.96 2.38 2.70 1.09 1.71 2.81
MIG-2 2737539  1.64  1.44  1.41  1.37  1.26  1.03  2.00  1.55  1.62  1.56  1.49
1448627  1.44  1.15  1.37  1.39  1.33  1.14  2.42  1.76  2.48  2.45  1.69
URP2 2848873 1.08 1.02 1.08 1.04  1.01 1.07  1.10  1.13  1.45  1.51  0.09
Breast URP1 2054929 1.36 1.66 1.22 1.31 1.31 1.27 1.28 1.76 1.47 1.81 1.45
MIG-2 5090449 2.23 1.71 1.87 1.49 1.46  1.28  1.22 1.06 2.67 2.92 1.29
Kidney URP1 2054929 1.30 0.00  1.24  1.18  1.73  1.52  1.08  1.21  1.40  1.10  0.92
MIG-2 5090449 1.09 0.00  1.87  1.60  1.55  1.68  1.41  1.10  1.19  1.30  1.06
Lung URP1 2054929 1.97 3.69 2.37 1.75 1.11 2.76 2.12 2.19 2.12 1.64 2.17
MIG-2 5090449  1.87 1.13 1.16 2.88 1.17  1.11 2.05 1.94 1.14 1.41 0.99
a Each tumor type represents a different set of patients.
b cDNA clones encoding parts of URP1, URP2 and MIG-2 in the colon tissue experiment utilized the Incyte GA chip set, whereas the remaining tissues
were analyzed using the Incyte HG chip set.
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increase utilizing RT-PCR on six tumor samples from
breast (Fig. 1A), colon (Fig. 1B) and lung (Fig. 1C). NoFig. 1. RT-PCR quantification of URP1 in tumor tissues. Fold increase in
URP1 expression compared to normal tissue expression in six (A) breast
tumors, (B) colon tumors, and (C) lung tumors. Normal tissues and tumor
tissues were normalized to GUS mRNA expression.increase was seen in any of the six breast tumor samples
consistent with the data from the microarray experiment
(Fig. 1A). In sharp contrast, significant increases in URP1
expression were seen in five of the six colon tumors (Fig.
1B, tumors 1, 2, 4–6) and in three of the six lung tumors
(Fig. 1C, tumors 2, 5 and 6). The average increase seen
in the colon and lung tumors was 3.95- and 59.82-fold,
respectively.
To elucidate the tissue distribution of URP1, Northern
blots of poly(A) selected mRNA from human brain, heart,
skeletal muscle, colon, thymus, spleen, kidney, liver, small
intestine, placenta, lung and peripheral blood leukocytes
were probed with a 690 base pair fragment of URP1
corresponding to the C-terminal base pairs 1342–2031
and, radiolabeled with [a-32P]dCTP (Fig. 2A). The stron-
gest signals are obtained from the brain and skeletal muscle
samples, while weak expression is seen in the kidney and
placenta samples, and little or no signal in the other tissues.
A single transcript of approximately 4.4 kb is detected in all
cases of expression. Similarly, the tissue expression of
URP2 was also examined by Northern analysis using a
full-length clone (Fig. 2B). A prominent band of approx-
imately 2.7 kb was detected in thymus, spleen and leukocyte
tissues, whereas faint bands could also be detected in lung
and placenta.
A full-length clone of 4720 bp encoding URP1 (Gen-
Bank accession number AF443278) was isolated by PCR
from a pool of human colon tumor cDNA. Considering
experimental error in the determination of the URP1 tran-
script by Northern analysis, the size is in relative agreement
with those results. Two full-length clones for URP2 were
isolated by a similar strategy. Sequencing of these clones
showed them to be 2477 and 2489 bp, differing by a 12 bp
internal insertion sequence. We refer to the clone which was
isolated from brain tissue lacking the 12 bp insert as URP2
short form (GenBank accession number AY093951) and the
clone that was isolated from leukocytes containing the
additional 12 bp sequence as URP2 long form (GenBank
accession number AY093952). We have also isolated a full-
Fig. 2. (A) Northern analysis of the URP1 gene. (B) Northern analysis of
the URP2 gene. The size and level of expression of the URP1 and URP2
mRNA was analyzed in 12 different human tissues. Molecular weight
markers in kilobases are indicated on the left side of the figure.
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number AF443279) and found that the previously described
clone is a partial cDNA (GenBank accession number
Z24725). Of the five full-length URP1 clones isolated and
sequenced, four clones contain a single base pair difference
from the genomic sequence in the Celera database and
results in a difference in a single amino acid, while one
clone contained two such differences. Ten clones for MIG-2
were picked and sequenced. All 10 clones contained a singlebase pair difference from the published sequence (GenBank
accession number Z24725) that causes a change from
isoleucine to valine at amino acid position 31 (ATC!
GTC). This amino acid difference was also confirmed on
the Celera human genome sequence.
An analysis of the URP1 cDNA for single nucleotide
polymorphisms (SNPs) revealed seven distinct variant posi-
tions; R425, Y472, Y569, Y2053, Y3856, V4451 and Y4462.
Interestingly, four of the SNPs occur in the protein-coding
region of the transcript and one of these (R425) results in a
missense mutation in which E and K are used interchange-
ably. Furthermore, the polymorphism rate for this gene is
3.5 greater than the predicted average gene exonic SNP
rate of two exonic SNPs/gene [16].
The predicted protein encoded by the URP1 gene
appears to utilize the first methionine codon (acaATG),
which is in acceptable initiation context [17]. In contrast,
the initiation codons for URP2 and MIG-2 are in excellent
translation context (gccATG). All three cDNAs contain the
in-frame termination codon, TAG, upstream to the initiator
methionine providing further evidence that the full-length
cDNA has been isolated for each gene. Presumably both
URP1 and URP2 have non-consensus polyadenylation
signals, AGTAAA, located 23 bp upstream and TATAAA,
located 21 bp upstream from the poly(A) addition site,
respectively. In contrast, the MIG-2 cDNA contains a
consensus polyadenylation signal 22 bp upstream from the
3Vend. The predicted URP1 protein is comprised of 677
amino acids with a predicted molecular mass of 77,408 Da
while URP2 has two isoforms, one with a predicted weight
of 75,434 Da (663 amino acids) and the other of 75,957 Da
(667 amino acids). MIG-2 protein is 680 residues and has a
predicted molecular weight of 77,860 Da.
A protein alignment between the three homologous
human gene products illustrates their degree of similarity
(Fig. 3A). URP1 and MIG-2 are most closely related, being
65.5% identical and 74.2% similar to one another, whereas
URP2 is more distantly related sharing 58.7% identity and
67.9% similarity to URP1 and 55.4% identity and 67.8%
similarity to MIG-2. A BLAST search of all protein
sequences in GenBank revealed that URP1 is strongly
related to three proteins from other species: C. elegans
UNC-112 and two Drosophila proteins CG14991 and
CG7729 (Fig. 3B). Comparison to these proteins reveals
that URP1 is 48.9% and 47.3% identical and 61.0% and
60.6% similar to the Drosophila proteins CG14991 and
CG7729, respectively. Furthermore, URP1 is 46.4% identi-
cal and 57.7% similar to the C. elegans UNC-112 protein.
URP1, URP2 and MIG-2 also share weak but significant
homology to human talin 1 [18] and talin 2 [19] as well as to
the talin homolog, filopodin, found in Dictyostelium dis-
coideum.
A determination and comparison of gene structure of
URP1, URP2 and MIG-2 was performed utilizing the
genomic sequence information in the Celera human sequence
database. This comparison revealed some striking similarities
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Fig. 4. Chromosomal location and exon– intron structure of the URP1, URP2 and MIG-2 genes. Ideograms of chromosomes 11, 14 and 20 are shown along
with the chromosomal location and exon structure of the URP1, URP2 and MIG-2 genes. All three homologs are comprised of 15 exons. The URP1 gene spans
about 50 kb and is located in 20p13 about 7–8 Mb from pter. URP2 is confined to about 20 kb in 11q12 about 10 Mb from the centromere. The MIG-2 gene is
spread across about 100 kb and is located in 14q22 about 33–34 Mb from pter.
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Table 2). Although the URP2 gene spans only about half of
the distance (f 20 kb) as URP1 and URP1 about half the
distance (f 50 kb) as MIG-2 (f 100 kb), all are transcribed
as 15 exons on the bottom strand of their respective
chromosomes, 20 (URP1), 11 (URP2) and 14 (MIG-2).
Their genomic organization relative to encoded protein is
almost exactly the same. In fact, exons 3, 6, 7, and 9–14 areFig. 3. (A) A multiple alignment of URP1 and its two human homologs, URP2 (lar
proteins are highlighted in black, whereas regions of similarity are highlighted in
and its amino acid is position numbered at the beginning of each row. (B) An align
two or more proteins are highlighted in black. Protein sequences used for the m
UNC-112 (GenBank accession numbers AAF47838, AAF49380, AAF20162, resof exactly the same size and contain precisely homologous
regions of each protein. Although the URP2 gene does
encode an alternate form which utilizes an alternative
acceptor site of exon 10 in leukocytes, 12 bp upstream of
the brain tissue acceptor site and results in larger form of the
protein containing a four amino acid insertion (IPRR)
between amino acids 360–361 (R–P) of the shorter form.
This insertion is illustrated in Fig. 2A and does notge form) and MIG-2. Amino acid regions of identity shared by two or more
gray. Gaps in the alignment are indicated by dashes. Each protein is labeled
ment of URP1 and its homologs in other species. Identical regions shared by
ultiple alignment were Drosophila CG14991 and CG7729 and C. elegans
pectively).
Table 2
Exon structure of URP1, URP2 and MIG-2 genes
Exon URP1 URP2 MIG-2 Exon function/size
Acceptor site Donor site Exon
size
Acceptor site Donor site Exon
size
Acceptor site Donor site Exon
size
comparison
1 GCGAG AGGAGgtggg 340 GAGAA GAAAGgtaag 81 GCCGC GCGCGgtgag 72 5VUTR
2 agcagACACC GATCAgtaag 169 tgtagCAGCA GATCAgtgag 174 cgcagGAAGG ACTCGgtgag 166 5VUTR and initiator ATG
3 tgcagATATA CCTGAgtaag 234 cacagATCGC CCTCAgtaag 234 tatagATGTA TTTTAgtaag 234 identical
4 tctagATATT ATCAGgtaag 147 xxxxxGCATC TGGGGxxxxx 120 aacagATATC ATCAGgtaag 135 exons of variable size but
5 tgcagTAAGT GCAGGgtaag 214 tccagGCGTG AGCAGgtgca 169 attagGAAGT CAAGGgtaag 226 homologous in function
6 tctagTTGGC CTAAAgtaag 103 cccagGTGGC CCAAGgtggg 103 tccagATGGC CAAAGgtacc 103 identical
7 tctagTATGA TACAGgtatg 108 tccagACAGA TGCAGgtacc 108 tgcagTATGA TGCAGgtagt 108 identical
8 tttagTACCA TTTTGgtatg 132 cctagTACCA TGCTGgtgag 135 ttcagTATCA TTTTGgtagg 135 1 AA deletion in URP1
9 cttagGAGGA TTTAGgtaag 50 catagGACAG TTTCGgtgag 50 cctagGGTGA TTCAAgtaag 50 identical
10 tgcagGCCCA TAGAGgtaag 125 cgaagGCCCC CAAGGgtaag 125 catagGCCAA CAGGGgtaag 125 identical
10a cccagCATCC CAAGGgtaag 137 4 AA insertion in alternate
URP2
11 ttcagGCTGC ACCATgtgag 107 tccagGCTGT AGGATgtgag 107 tacagGATGT ACAATgtaag 107 identical
12 tgcagGAGAA AACAGgtact 222 cccagGAGCA AGCAGgtacc 234 tccagGAAAA AGCAGgtact 222 identical
13 ttcagCTGGC GTCAGgtgat 125 cgcagCTCAC GTCAGgtatg 125 tttagATAAC GCAAGgtcag 125 identical
14 ttcagATTTA GGCAGgtaaa 142 gccagGTTCA GGCAGgtggg 142 tatagGGTTC AAATGgtaaa 142 identical
15 tccagGTGGT ATTTG 2502 ttcagGTGGC ATTGT 570 tccagGTCAC TATTT 1276 STOP codon and 3VUTR
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homologs. The remaining exons of each homolog contain
corresponding analogous regions of each transcript although
their size differs. Exon 1 of all three genes contains the 5V
UTR and exon 2 contains an additional part of the 5VUTR
as well as the initiator methionine. Exons 4 and 5 are
variable in size in each gene but together still contain
homologous regions of each protein. URP1 has a deletion
of one amino acid in exon 8 relative to URP2 and MIG-2.
Finally, exon 15 of all genes contains the termination codon
and 3VUTR, although the untranslated region differs greatly
in size. This highly conserved exon–intron structure sug-
gests that all three genes arose by gene duplication from a
single ancestral gene.
A review of the literature finds no attributed function
for any of the protein homologs although a homozygous
mutant of the UNC-112 gene in C. elegans results in aFig. 5. Domain structure of URP1, URP2 and MIG-2-related proteins. Each protein
right. The position of each domain is also shown with FERM domains illustratedphenotype that is unable to properly organize integrin
proteins in the plasma membrane [3]. This protein appears
to localize to the inner surface of the plasma membrane
and co-localizes with integrin at cell–matrix adhesion
complexes.
A more detailed analysis of the protein domains of all
of the genes in this unique family reveals that each
member contains two domain types (Fig. 5). Each protein
contains two FERM flanking a PH domain near the C-
terminal half of the protein. FERM domains are present
in structural and signal proteins such as myosins and
protein tyrosine phosphatases. The PH domain has been
shown to be an internal plasma membrane-binding
region, which plays structural and regulatory roles in
the assembly and stabilization of specialized plasma
membrane domains. This domain is also commonly found
in many eukaryotic signaling proteins. The domain familyis depicted as a solid line with the total number of amino acids listed at the
as shaded boxes and PH domains as white boxes.
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bind inositol phosphates, and various other proteins.4. Discussion
Although the proportion of genetic changes which occur
in cancer that are reflected at the RNA level is not certain,
carcinoma samples have shown a number of genes to be up-
regulated when compared to normal tissue [20–23]. These
genes can come from a variety of functional classes,
including metastasis, cell cycle, adhesion and metabolism.
We have identified and cloned one such gene, which we call
URP1 for Unc-112 related protein-1. URP1 is over-
expressed in 7 out of 10 colon and 6 out of 10 lung
carcinomas. By RT-PCR the magnitude of this increase
was shown to approximately 60-fold in lung tumors and
about 4-fold in colon tumors.
In addition to generating the full-length clone of URP1,
we also found that the described clone of MIG-2 was only a
partial sequence and obtained the full-length sequence of
this gene as well. Not only do these two genes have a high
level of homology to each other at the protein level, but they
also share remarkable conservation of their intron–exon
boundaries. In a comprehensive search of the genome, we
have identified and cloned the final member of this novel
family of proteins, URP2. The expression levels of this
gene, like those of MIG-2, are not significantly increased in
various cancer tissues.
The role of URP1 in cancer is currently unclear. Exami-
nation of its ortholog, C. elegans UNC-112, may help bring
about an understanding of its potential function. An UNC-
112 fusion protein with GFP was shown to co-localize with
PAT-3/h-integrin in dense bodies and M-lines at the muscle
cell membrane. Furthermore, a UNC-112 knockout shows
this protein to be crucial in the organization of h-integrin after
it has inserted into the basal cell membrane. It is not clear
from this work whether UNC-112 interacts directly with h-
integrin or through an additional protein or proteins [3].
The absence of a signal peptide, transmembrane domain,
or nuclear localization sequence in conjunction with the
presence of multiple FERM domains further leads one to
conclude that URP1 is intracellular and may be linked to the
plasma membrane. FERM domain-containing proteins have
been routinely identified as membrane-cytoskeleton linkers.
Depletion of these proteins through introduction of anti-
sense oligonucleotides shows that FERM domain-contain-
ing proteins play a role in integrin- and cadherin-based
adheren junctions [24]. The belief that URP1 may be
associated with integrin family members is strengthened
by the existence of a PH domain. PH domains, initially
identified in pleckstrin, have been documented in a variety
of membrane-anchored proteins involved in signal trans-
duction [9].
Further insight into the potential function of URP1 may
be gained from its homology to talin. These two proteinsare conserved between amino acids 173 and 407. This
homology occurs within the FERM domain of talin, which
has been implicated as the binding domain for h-integrin
cytoplasmic tails, and consists of the N-terminal 433
amino acids [25]. Talin is one of a number of proteins
that are involved in coupling membrane proteins to cytos-
keletal structures and signaling pathways. Talin is thought
to mediate this linkage through its binding sites for h-
integrin, cytoskeletal proteins such as actin, and signaling
proteins such as focal adhesion kinase (FAK). Decreased
expression of talin leads to decreased expression of some
integrins on the cell surface and consequently decreased
cell migration and causes impaired focal adhesion forma-
tion [26,27]. The link between these types of proteins and
the phenotype of cell migration may explain the apparent
up-regulation of URP1 in carcinoma cells. As is the case
with the other 20 proteins known to bind to integrin
cytoplasmic domains, talin binding is specific to some h-
integrin tails (h1A, h1D, h2 and h3) both in vivo and in
vitro, while failing to bind others [28]. The possibility that
URP1 binds to a specific subset of integrins in a similar
way remains to be tested.
The most compelling evidence to date concerning the
prospect that URP1 may bind to integrins can be seen in the
recent work concerning the proteins PAT-4/ILK and UNC-
112. The C. elegans gene PAT-4 has 56% identity to the
human gene integrin-linked kinase (ILK). PAT-4/ILK has
been shown to co-localize with PAT-3/h-integrin, but to be
mislocalized in unc-112 mutants [29]. Yeast-two-hybrid
studies then verified that PAT-4/ILK directly binds UNC-
112. This is especially relevant when one considers that
human ILK is involved in multiple events associated with
oncogenesis. These include inhibition of programmed cell
death, cellular migration, and invasion (reviewed in Ref.
[30]). Increased ILK expression leads to anchorage-inde-
pendent growth of cells in vitro, and formation of tumors
when inoculated into murine models. Furthermore, ILK
expression has been shown to be elevated in human colon
and prostate carcinomas [31,32]. The apparent requirement
of UNC-112 for proper PAT-4/ILK localization may account
for the over-expression of URP1 in tumors. The possible
correlation between expression of ILK and URP1 remains to
be fully elucidated.
Determination of whether or not URP1 is sufficient to
induce changes in cells resembling a transformed state
will require over-expression studies of this gene in various
cell types. The immediate importance of URP1 lies in its
potential to serve as a strongly associated marker of
disseminated disease. Over-expression of the well-charac-
terized HER-2/neu gene, which has been shown to be an
important factor in breast cancer prognosis, is only
associated with about 30% of breast tumors [33].
Recently, the clinical significance of HER-2/neu expres-
sion in lung cancer was evaluated and shown to be over-
expressed only 2–3-fold in about 20% of patient samples
[34]. By comparison, it appears that URP1 over-expres-
E.J. Weinstein et al. / Biochimica et Biophysica Acta 1637 (2003) 207–216216sion is more closely associated with lung and colon
cancer occurring in 60% and 70% of the tumors, respec-
tively. Therefore, either alone, or in combination with
other tumor markers, URP1 has the potential to be of both
prognostic and diagnostic value for cases of colon or lung
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